Gene Expression Profiles to Categorize Wilms Tumors
Status: | Recruiting |
---|---|
Conditions: | Cancer, Cancer, Kidney Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 4/21/2016 |
Start Date: | February 2004 |
Categorization of Wilms Tumors by Genetic Expression
This laboratory study is using gene expression profiling to identify different categories of
Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with
cancer may help doctors identify biomarkers related to cancer.
Wilms tumors. Studying the genes expressed in samples of tumor tissue from patients with
cancer may help doctors identify biomarkers related to cancer.
OBJECTIVES:
I. Identify new molecular categories of Wilms tumor (WT) based on the gene expression
profiles of samples from patients with this disease.
II. Develop a classifying system (classifier) that will predict a defined number of
clinically relevant categories based on expression of an established set of genes.
III. Confirm and test the classifier with further analysis of the genes by several different
methodologies, using additional patient samples that are outside of the case/cohort but
which possess the clinically or scientifically relevant parameter.
IV. Validate the use of the classifier to predict defined groups within a second set of
samples (for which investigators are blinded to the clinical and biological data) by
subsequent comparison with true incidence of pertinent markers.
OUTLINE:
Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix
assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An
additional 300 specimens are examined for gene expression and categorized according to the
classifiers.
I. Identify new molecular categories of Wilms tumor (WT) based on the gene expression
profiles of samples from patients with this disease.
II. Develop a classifying system (classifier) that will predict a defined number of
clinically relevant categories based on expression of an established set of genes.
III. Confirm and test the classifier with further analysis of the genes by several different
methodologies, using additional patient samples that are outside of the case/cohort but
which possess the clinically or scientifically relevant parameter.
IV. Validate the use of the classifier to predict defined groups within a second set of
samples (for which investigators are blinded to the clinical and biological data) by
subsequent comparison with true incidence of pertinent markers.
OUTLINE:
Three hundred tumor specimens are analyzed for genetic expression profiles using Affymetrix
assays. Specific genes are identified as classifiers and analyzed using tissue arrays. An
additional 300 specimens are examined for gene expression and categorized according to the
classifiers.
Inclusion Criteria:
- Specimens from patients previously enrolled as "On Study" or "Followed Biology Only"
on protocol NWTSG-5 (COG-Q9401)
- Study follow-up data for disease status available
- National Wilms Tumor Study Group/Children's Oncology Group pathology review showing
"favorable" histology
- Sufficient biology samples available without using biology bank reserves
We found this trial at
2
sites
901 45th St
West Palm Beach, Florida 33407
West Palm Beach, Florida 33407
(561) 844-6300
Principal Investigator: Narayana Gowda, MD
Phone: 561-844-6363
Saint Mary's Hospital Our team of dedicated physicians, nurses and staff offer a broad spectrum...
Click here to add this to my saved trials
440 E Huntington Dr
Arcadia, California 91006
Arcadia, California 91006
(626) 447-0064
Principal Investigator: Elizabeth J. Perlman, MD
Phone: 773-880-4306
Children's Oncology Group The Children's Oncology Group (COG), a National Cancer Institute supported clinical trials...
Click here to add this to my saved trials